Harun Muayad Said
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Harun Muayad Said has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
Michael Flentje
Department of Radiation Oncology, University of Würzburg, Würzburg, Germany
14 shared publicationsDirk Vordermark
11 shared publicationsAstrid Katzer
Department of Radiation Oncology, University of Würzburg, Würzburg, Germany
10 shared publicationsCarsten Hagemann
Department of Neurosurgery, University of Würzburg, Würzburg, Germany
9 shared publicationsJelena Anacker
8 shared publicationsAdrian Staab
7 shared publications
Latest Publications
- Open Access
- 5 January 2021
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 46 (4) , 445-454
Evaluation of potential tumor markers that may predict neoadjuvant treatment efficiency in rectal cancer
Objectives: The recurrence of rectal cancer or its resistance to neoadjuvant treatment develops due to the adaptation to hypoxia, apoptosis or autophagy. Survivin, one of the inhibitors of apoptosis; Beclin 1, which is a positive regulator in the autophagy pathway; and hypoxia-inducible factor-1α (HIF-1α) and carbonic anhydrase-9 (CA9), which are associated with tumor tissue hypoxia, may be related to resistance to treatment. Our aim was to evaluate the potential tumor markers that may help to monitor the response to neoadjuvant treatment in locally advanced rectal cancer (RC). Methods: Twenty-five patients with locally advanced RC were included in the study. Gene expression and protein levels of Beclin 1, Survivin, HIF-1α, and CA9 were analyzed in fresh tissue specimens and blood samples. The relationships of these markers to tumor staging and regression grade were evaluated. Results: Higher blood CA9 gene expression levels and lower blood HIF-1α protein levels were found in the response group according to tumor regression grade. After neoadjuvant treatment, tissue Beclin 1 and blood Survivin gene expressions and tissue CA9, blood Beclin 1 and blood HIF-1α protein levels decreased significantly. Conclusion: Beclin 1, Survivin, HIF-1α ve CA9 may help to predict the effects of the applied treatment approach.
- 5 January 2021
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 46 (4) , 445-454
Open AccessEvaluation of potential tumor markers that may predict neoadjuvant treatment efficiency in rectal cancer
Objectives: The recurrence of rectal cancer or its resistance to neoadjuvant treatment develops due to the adaptation to hypoxia, apoptosis or autophagy. Survivin, one of the inhibitors of apoptosis; Beclin 1, which is a positive regulator in the autophagy pathway; and hypoxia-inducible factor-1α (HIF-1α) and carbonic anhydrase-9 (CA9), which are associated with tumor tissue hypoxia, may be related to resistance to treatment. Our aim was to evaluate the potential tumor markers that may help to monitor the response to neoadjuvant treatment in locally advanced rectal cancer (RC). Methods: Twenty-five patients with locally advanced RC were included in the study. Gene expression and protein levels of Beclin 1, Survivin, HIF-1α, and CA9 were analyzed in fresh tissue specimens and blood samples. The relationships of these markers to tumor staging and regression grade were evaluated. Results: Higher blood CA9 gene expression levels and lower blood HIF-1α protein levels were found in the response group according to tumor regression grade. After neoadjuvant treatment, tissue Beclin 1 and blood Survivin gene expressions and tissue CA9, blood Beclin 1 and blood HIF-1α protein levels decreased significantly. Conclusion: Beclin 1, Survivin, HIF-1α ve CA9 may help to predict the effects of the applied treatment approach.
- 22 May 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (1) , 1357-1365
Blood‑based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer‑risk stratification
Prostate cancer (PCa) is the second most diagnosed malignancy, and the leading cause of cancer‑associated mortality among males. Prostate‑specific antigen (PSA) has long been used for the detection of PCa. However, PSA levels increase in PCa and benign prostatic hyperplasia (BPH), and are associated with a poor disease outcome. Circulating microRNAs (miRNAs) have been determined to be highly stable in the circulation, and could be utilized as biomarkers to improve disease diagnosis and management. In the present study, the effectiveness of four PCa‑associated miRNAs in the discrimination of PCa from BPH and the risk‑stratification of PCa was assessed. The study included 100 participants: 35 patients with localized PCa, 35 patients with BPH and 30 healthy subjects. Patients with PCa were categorized based on their tumor stage (T), PSA level and Gleason score (GS) into low‑(T 1/2, PSA 20 ng/ml or GS ≥8). Reverse transcription‑quantitative polymerase chain reaction was employed to assess the miRNA expression in peripheral blood samples. Significantly reduced expression of miR‑15a, miR‑126, miR‑192 and miR‑377 was observed in patients with PCa compared with patients with BPH and healthy subjects. In addition, the expression of the four miRNAs was lower in high‑risk PCa patients than in low‑risk PCa patients, with miR‑126 being the most downregulated. The expression of the four miRNAs was also significantly and independently associated with PCa. Receiver operating characteristic curve analysis revealed a significant ability of the miRNAs to distinguish patients with PCa from those with BPH, patients with PCa from controls and low‑risk PCa from high‑risk PCa. These data suggested that expression of these miRNAs in the blood circulation may be promising, non‑invasive biomarkers for the early detection of localized PCa, and for PCa risk stratification. Further validations of the clinical implementation of these results are warranted in a larger cohort.
- 22 May 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (1) , 1357-1365
Blood‑based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer‑risk stratification
Prostate cancer (PCa) is the second most diagnosed malignancy, and the leading cause of cancer‑associated mortality among males. Prostate‑specific antigen (PSA) has long been used for the detection of PCa. However, PSA levels increase in PCa and benign prostatic hyperplasia (BPH), and are associated with a poor disease outcome. Circulating microRNAs (miRNAs) have been determined to be highly stable in the circulation, and could be utilized as biomarkers to improve disease diagnosis and management. In the present study, the effectiveness of four PCa‑associated miRNAs in the discrimination of PCa from BPH and the risk‑stratification of PCa was assessed. The study included 100 participants: 35 patients with localized PCa, 35 patients with BPH and 30 healthy subjects. Patients with PCa were categorized based on their tumor stage (T), PSA level and Gleason score (GS) into low‑(T 1/2, PSA 20 ng/ml or GS ≥8). Reverse transcription‑quantitative polymerase chain reaction was employed to assess the miRNA expression in peripheral blood samples. Significantly reduced expression of miR‑15a, miR‑126, miR‑192 and miR‑377 was observed in patients with PCa compared with patients with BPH and healthy subjects. In addition, the expression of the four miRNAs was lower in high‑risk PCa patients than in low‑risk PCa patients, with miR‑126 being the most downregulated. The expression of the four miRNAs was also significantly and independently associated with PCa. Receiver operating characteristic curve analysis revealed a significant ability of the miRNAs to distinguish patients with PCa from those with BPH, patients with PCa from controls and low‑risk PCa from high‑risk PCa. These data suggested that expression of these miRNAs in the blood circulation may be promising, non‑invasive biomarkers for the early detection of localized PCa, and for PCa risk stratification. Further validations of the clinical implementation of these results are warranted in a larger cohort.
- Open Access
- 25 October 2017
- Published by IntechOpen
Anatomic Origin and Molecular Genetics in Neuroblastoma
Neuroblastoma is considered as the most common extracranial solid tumor occurring during childhood, but takes place rarely after the age of 10 years. The tumors are considered as embryonal tumors that result from the fetal or early postnatal life development and are formed from neural crest-derived cells, and their origination is from the early nerve cells which are called as neuroblasts of sympathetic nervous system. Being heterogeneous in their biological, genetic, and morphological characteristics, tumors which are distinct from other solid tumors due to their biological heterogeneity result in the clinical pattern changes from spontaneous regression to a highly aggressive metastatic disease. Neuroblastoma tumorigenesis is regulated by Myc oncogene, leading to aggressive tumor subset. Many epigenetic factors play crucial role in the disease induction and development, while regulatory effect and outcome result in epigenetic patterns distinguishing neuroectoderm, neural crest, and more mature neural states. Neuroblastoma patients’ clinical management is based on prognostic categories subtracted from studies correlating outcome and clinico-biological variables. Neuroblastoma anatomic boundaries include primarily autonomic nervous system besides other rare locations. Neuroblastoma molecular pathogenesis classifies the tumor according to the different clinical behaviors that are important for the improvement of the patients outcome and overall survival according to the different therapy modalities applied.
- 25 October 2017
- Published by IntechOpen
Open AccessAnatomic Origin and Molecular Genetics in Neuroblastoma
Neuroblastoma is considered as the most common extracranial solid tumor occurring during childhood, but takes place rarely after the age of 10 years. The tumors are considered as embryonal tumors that result from the fetal or early postnatal life development and are formed from neural crest-derived cells, and their origination is from the early nerve cells which are called as neuroblasts of sympathetic nervous system. Being heterogeneous in their biological, genetic, and morphological characteristics, tumors which are distinct from other solid tumors due to their biological heterogeneity result in the clinical pattern changes from spontaneous regression to a highly aggressive metastatic disease. Neuroblastoma tumorigenesis is regulated by Myc oncogene, leading to aggressive tumor subset. Many epigenetic factors play crucial role in the disease induction and development, while regulatory effect and outcome result in epigenetic patterns distinguishing neuroectoderm, neural crest, and more mature neural states. Neuroblastoma patients’ clinical management is based on prognostic categories subtracted from studies correlating outcome and clinico-biological variables. Neuroblastoma anatomic boundaries include primarily autonomic nervous system besides other rare locations. Neuroblastoma molecular pathogenesis classifies the tumor according to the different clinical behaviors that are important for the improvement of the patients outcome and overall survival according to the different therapy modalities applied.
- 3 May 2017
- Published by Spandidos Publications in Oncology Reports
- Vol. 37 (6) , 3625-3634
Time- and oxygen-dependent expression and regulation of NDRG1 in human brain cancer cells
N-myc downstream-regulated gene 1 (NDRG1) is a tumor suppressor with the potential to suppress metastasis, invasion and migration of cancer cells. It is regulated under stress conditions such as starvation or hypoxia. NDRG1 regulation is both induced and controlled by HIF-1α-dependent and -independent pathways under hypoxic conditions. However, there are profound differences in the way NDRG1 expression is regulated by HIF-1α and other transcription factors. Therefore, we aimed to define the time-dependent pattern of NDRG1 mRNA and protein expression in human glioblastoma cell lines in extreme hypoxia and after re-oxygenation as well as under normoxic conditions. Furthermore, we ascribe the regulation of NDRG1 to the transcription factors HIF-1α, SP1, CEBPα, YB-1 and Smad7 in a time-dependent manner. The human malignant glioma cell lines U87-MG, U373 and GaMG were cultured for 1, 6 and 24 h under hypoxic (0.1% O2) conditions and then they were re-oxygenated. The mRNA expression of NDRG1, HIF-1α SP1, CEBPα, YB-1 and Smad7 was measured using semi-quantitative RT-PCR analysis. Their protein expression was analyzed using western blotting. Our experiments revealed that long-term (24 h), but not short-term hypoxia led to the induction of NDRG1 expression in human glioma cell lines. NDRG1 expression was found to correlate with the protein expression of HIF-1α, SP1, CEBPα, YB-1 and Smad7. The present study suggests for the first time that SP1 regulates NDRG1 expression in glioma cells under hypoxia in a time-dependent manner along with HIF-1α, CEBPα, YB-1 and Smad7. These molecules, each separately or in combination, may possess the potential to become target molecules for antitumor therapeutic approaches particularly in human brain tumors.
- 3 May 2017
- Published by Spandidos Publications in Oncology Reports
- Vol. 37 (6) , 3625-3634
Time- and oxygen-dependent expression and regulation of NDRG1 in human brain cancer cells
N-myc downstream-regulated gene 1 (NDRG1) is a tumor suppressor with the potential to suppress metastasis, invasion and migration of cancer cells. It is regulated under stress conditions such as starvation or hypoxia. NDRG1 regulation is both induced and controlled by HIF-1α-dependent and -independent pathways under hypoxic conditions. However, there are profound differences in the way NDRG1 expression is regulated by HIF-1α and other transcription factors. Therefore, we aimed to define the time-dependent pattern of NDRG1 mRNA and protein expression in human glioblastoma cell lines in extreme hypoxia and after re-oxygenation as well as under normoxic conditions. Furthermore, we ascribe the regulation of NDRG1 to the transcription factors HIF-1α, SP1, CEBPα, YB-1 and Smad7 in a time-dependent manner. The human malignant glioma cell lines U87-MG, U373 and GaMG were cultured for 1, 6 and 24 h under hypoxic (0.1% O2) conditions and then they were re-oxygenated. The mRNA expression of NDRG1, HIF-1α SP1, CEBPα, YB-1 and Smad7 was measured using semi-quantitative RT-PCR analysis. Their protein expression was analyzed using western blotting. Our experiments revealed that long-term (24 h), but not short-term hypoxia led to the induction of NDRG1 expression in human glioma cell lines. NDRG1 expression was found to correlate with the protein expression of HIF-1α, SP1, CEBPα, YB-1 and Smad7. The present study suggests for the first time that SP1 regulates NDRG1 expression in glioma cells under hypoxia in a time-dependent manner along with HIF-1α, CEBPα, YB-1 and Smad7. These molecules, each separately or in combination, may possess the potential to become target molecules for antitumor therapeutic approaches particularly in human brain tumors.
- Open Access
- 1 January 2015
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 6 (9) , 849-858
Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer disease. Here we examined Nampt expression in patients with CRC and the effect of Nampt on cell viability in CRC cells. Nampt protein was overexpressed in colorectal adenoma as well as colorectal carcinoma. The immunoreactive staining of Nampt was negative in the adjacent normal colorectal tissue, weak in colorectal adenoma, and strong in colorectal carcinoma, which may represent tumor progression. Further evaluation of clinical data showed that Nampt expression was not correlated with the clinicopathological characteristics of CRC. Additionally, our in vitro studies demonstrated that Nampt promotes CRC cell viability, whereas the Nampt inhibitor FK866 suppressed CRC cell viability, which was in concordance with the previous studies in other cancer cells. Treatment with Nampt-siRNA reduced the Nampt protein expression resulting in the inhibition of the cell viability of HCT116 and Caco2. Thus, the involvement of Nampt in cell growth indicates that Nampt may play an important role in colorectal tumorigenesis. As a consequence, our results suggest that Nampt may be considered as a progression marker of colorectal tumor and a potentially therapeutic target for the treatment of CRC.
- 1 January 2015
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 6 (9) , 849-858
Open AccessRegulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer disease. Here we examined Nampt expression in patients with CRC and the effect of Nampt on cell viability in CRC cells. Nampt protein was overexpressed in colorectal adenoma as well as colorectal carcinoma. The immunoreactive staining of Nampt was negative in the adjacent normal colorectal tissue, weak in colorectal adenoma, and strong in colorectal carcinoma, which may represent tumor progression. Further evaluation of clinical data showed that Nampt expression was not correlated with the clinicopathological characteristics of CRC. Additionally, our in vitro studies demonstrated that Nampt promotes CRC cell viability, whereas the Nampt inhibitor FK866 suppressed CRC cell viability, which was in concordance with the previous studies in other cancer cells. Treatment with Nampt-siRNA reduced the Nampt protein expression resulting in the inhibition of the cell viability of HCT116 and Caco2. Thus, the involvement of Nampt in cell growth indicates that Nampt may play an important role in colorectal tumorigenesis. As a consequence, our results suggest that Nampt may be considered as a progression marker of colorectal tumor and a potentially therapeutic target for the treatment of CRC.
- 1 July 2013
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 21 (13) , 3949-3957
Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including Acetazolamide in human Glioblastoma
- 1 July 2013
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 21 (13) , 3949-3957
Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including Acetazolamide in human Glioblastoma
- 1 May 2013
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 403-407
Determination human brain tumor marker gene carbonic anhydrase 9 (CA9) gene expression in different type of brain tumor cells
The hypoxia-inducible enzyme carbonic anhydrase IX (CA-IX) is considered as a surrogate marker of tumor hypoxia, prognosis indicator and a potential the expression pattern of the human tumor hypoxia marker gene CA-IX protein, CA9-mRNA and hypoxia-inducible factor-In (HIF-1α) protein levels in GaMG cells exposed to in vitro hypoxia (1, 6 or 24 h at 5%, 1 % or 0.1 % 02). All cell lines displayed a strong hypoxic induction of CA9-mRNA in response to prolonged severe hypoxia with cell-line specific patterns at moderate to mild hypoxia and shorter treatment times. In GaMG cell lines, a marked induction of CA-IX protein in response to severe hypoxia was seen. CA-IX over expression was paralleled by the results for HIF-1α protein. CA-IX expression pattern in human malignant glioblastoma cells (GBM) resulted from low oxygen concentrations or constitutive, oncogene-related, over expression is considered prognostically relevant.
- 1 May 2013
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 403-407
Determination human brain tumor marker gene carbonic anhydrase 9 (CA9) gene expression in different type of brain tumor cells
The hypoxia-inducible enzyme carbonic anhydrase IX (CA-IX) is considered as a surrogate marker of tumor hypoxia, prognosis indicator and a potential the expression pattern of the human tumor hypoxia marker gene CA-IX protein, CA9-mRNA and hypoxia-inducible factor-In (HIF-1α) protein levels in GaMG cells exposed to in vitro hypoxia (1, 6 or 24 h at 5%, 1 % or 0.1 % 02). All cell lines displayed a strong hypoxic induction of CA9-mRNA in response to prolonged severe hypoxia with cell-line specific patterns at moderate to mild hypoxia and shorter treatment times. In GaMG cell lines, a marked induction of CA-IX protein in response to severe hypoxia was seen. CA-IX over expression was paralleled by the results for HIF-1α protein. CA-IX expression pattern in human malignant glioblastoma cells (GBM) resulted from low oxygen concentrations or constitutive, oncogene-related, over expression is considered prognostically relevant.
- Open Access
- 1 January 2012
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 3 (7) , 104-110
Inhibition of N-Myc down regulated gene 1 inin vitrocultured human glioblastoma cells
Inhibition of N-Myc down regulated gene 1 in in vitro cultured human glioblastoma cells
- 1 January 2012
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 3 (7) , 104-110
Open AccessInhibition of N-Myc down regulated gene 1 inin vitrocultured human glioblastoma cells
Inhibition of N-Myc down regulated gene 1 in in vitro cultured human glioblastoma cells
- Open Access
- 1 January 2012
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 3 (6) , 82-91
Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cellsin vitro
Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro
- 1 January 2012
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 3 (6) , 82-91
Open AccessHypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cellsin vitro
Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro